What Atavistik Bio does

Atavistik Bio is a clinical-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts, that develops precision allosteric small molecule therapeutics for metabolic diseases and cancer. The company's discovery engine is the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, which combines the licensed-in MIDAS technology (mass spectrometry integrated with equilibrium dialysis, developed at the University of Utah by co-founder Jared Rutter and published in Science in 2023), AI-enabled informatics via a partnership with Plex Research, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins that are inaccessible to conventional orthosteric approaches. This platform has generated an internal pipeline led by ATV-1601, an oral allosteric AKT1-selective inhibitor that received FDA IND clearance and Fast Track Designation in June 2026 for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT Phase 1/2 study, and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms currently in lead optimization.

The company targets diseases with high unmet need and no or limited approved therapies: HHT affects more than 1.6 million people globally and 80,000+ in the US, while myeloproliferative neoplasms affect 300,000+ patients in the US with current pan-JAK inhibitors limited by tolerability and inability to suppress mutant allele burden. Atavistik has assembled a senior leadership team with lineage from Blueprint Medicines, Agios Pharmaceuticals, Fulcrum Therapeutics, Servier, and Sage Therapeutics, and is supported by top-tier life sciences investors including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management, with cumulative disclosed funding of approximately $260 million since inception.

Atavistik's business model is a hybrid of internal pipeline development and platform licensing. Revenue, once generated, is expected to come from drug commercialization, milestone payments, and royalties from collaborative agreements. The company advanced a research collaboration with Pfizer in January 2025 to apply the AMPS platform against two undisclosed oncology targets, with Pfizer holding an option to license resulting programs, providing a non-dilutive capital pathway alongside equity financing. The company is pre-revenue, has no commercial products, and channels outputs through traditional pharmaceutical distribution upon regulatory approval or via licensing to larger partners.

Name

Atavistik Bio

Legal name

Atavistik Bio, Inc.

Website

https://atavistikbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for Hereditary Hemorrhagic Telangiectasia, myeloproliferative neoplasms, and oncology using its proprietary AMPS metabolite-protein screening platform.

Ownership category

akta.pro rank

Product category

Precision Allosteric Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Allosteric small molecules
• Precision oncology therapeutics
• Rare hematology treatments
• Metabolite-protein screening platform
• Structure-based drug design

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Future Drug Development and Commercialization: Pre-revenue clinical stage biotechnology company. Plans to develop and commercialize novel allosteric therapeutics internally and through licensing partnerships. Revenue will come from drug sales, milestone payments, and royalties from collaborative agreements.
2. Collaborations and Licensing: Strategic partnerships with pharmaceutical companies for platform utilization and program licensing. Pfizer collaboration for oncology targets represents a licensing model where Pfizer can license programs after research period. Atavistik retains internal pipeline development rights while extending platform reach through partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for metabolic diseases and cancer. Its lead asset, ATV-1601, is an oral AKT1-selective inhibitor in Phase 1/2 for Hereditary Hemorrhagic Telangiectasia (HHT), with a JAK2 V617F mutant-selective inhibitor program in lead optimization for myeloproliferative neoplasms (MPNs). Discovery is powered by the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform that combines metabolite-protein screening, AI-enabled analysis, and structure-based drug design.

Product overview

Atavistik Bio is a clinical stage biotechnology company developing a portfolio of selective allosteric therapeutics. The company's core product is ATV-1601, an oral allosteric AKT1-selective inhibitor currently in Phase 1/2 clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT study. The pipeline also includes a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms in lead optimization stage. The AMPS (Atavistik Metabolite-Protein Screening) platform serves as the foundational technology enabling the discovery of these allosteric therapeutics by leveraging metabolite-protein interactions, AI-enabled analysis, and structure-based drug design. Internal development focuses on rare hematology, while strategic partnerships (including with Pfizer in oncology) extend the platform's reach across therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• ATV-1601 Oral allosteric AKT1-selective inhibitor being evaluated for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder. Designed to selectively target AKT1 to address vascular pathology across ALK1, ENG, and SMAD4 mutations.
• JAK2 V617F Mutant-Selective Inhibitor Program Allosteric inhibitor program targeting the JAK2 V617F mutation for myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and myelofibrosis). Binds the pseudokinase JH2 domain to selectively inhibit mutant JAK2 while sparing wild-type JAK2.
• AMPS (Atavistik Metabolite-Protein Screening) Platform Proprietary drug discovery platform combining metabolite-protein interaction screening, AI-enabled discovery, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins. Leveraged internally for pipeline development and offered to pharmaceutical partners through research collaborations and licensing.

Quantifiable outcome

• ATV-1601 demonstrated favorable safety profile in Phase 1 oncology study, validating differentiated selectivity over pan-AKT inhibitors
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• PfizercoreStrategic or Co-development Partner · 2 January 2025Research collaboration where Atavistik Bio leverages its proprietary AMPS platform to identify novel allosteric binders against two undisclosed Pfizer-designated oncology targets. At completion of research period, Pfizer has option to license the programs. Collaboration enables Atavistik to extend platform reach to broader oncology indications while progressing internal pipeline.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Blueprint Medicines: Precision medicine biotech focused on kinase inhibitors for oncology and rare diseases. Most directly comparable given shared leadership lineage (Atavistik's CSO Marion Dorsch was previously CSO at Blueprint Medicines) and similar allosteric/inhibitor approach to historically intractable targets.
• Agios Pharmaceuticals: Metabolism-focused drug discovery company developing therapies for cancer and rare genetic diseases. Multiple Atavistik senior leaders are Agios alumni (CSO, VP Biology, VP Platform, VP Regulatory, VP Clinical Science), and the metabolism-based approach to drug discovery is highly aligned.
• Revolution Medicines: Precision oncology company developing allosteric inhibitors of key oncogenic drivers. Directly comparable for its allosteric approach to difficult oncology targets and its emphasis on selective modulation of disease-causing proteins.
• Relay Therapeutics: Precision medicine company using motion-based structural insights and computational chemistry to design allosteric and selective inhibitors. Comparable for its emphasis on allosteric targeting and platform-enabled precision oncology discovery.
• Black Diamond Therapeutics: Precision oncology company developing allosteric inhibitors across multiple targets. Comparable for its allosteric approach to difficult-to-drug oncogenic targets and its platform-driven pipeline strategy.
• Foghorn Therapeutics: Precision oncology company targeting chromatin regulatory complexes. Comparable for its platform-enabled discovery of selective modulators against historically intractable oncology targets and similar scientific approach to protein modulation.
• Fulcrum Therapeutics: Clinical-stage biopharmaceutical company developing therapies for genetically defined rare diseases. Atavistik's CEO Bryan Stuart was previously CEO of Fulcrum, and the companies share rare-disease focus with selective small-molecule approaches.
• Erasca: Precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable for its emphasis on selective targeting of historically intractable oncology targets and clinical-stage development.

Emerging players

• Schrödinger: Computational drug discovery platform company combining physics-based simulation with AI/ML to accelerate small molecule discovery. Comparable for its platform-based business model combining computational tools with therapeutic programs, though broader in scope than Atavistik's metabolite-protein focus.
• Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-throughput experimental biology with machine learning. Comparable for its AI-driven discovery platform approach, though Atavistik focuses specifically on metabolite-protein interactions while Recursion uses image-based phenotypic screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atavistik-bio
• Xx.com/AtavistikBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atavistik Bio